^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Trk inhibitor

    Related drugs:
    Apply
    A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) (NCT02637687)
    Phase 1/2
    Bayer
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/16/2015
    Primary completion :
    07/20/2024
    Completion :
    09/30/2026
    NTRK3 • ETV6 • NTRK
    |
    NTRK positive • NTRK fusion
    |
    carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (CARE study) (NCT04094610)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/12/2020
    Primary completion :
    09/30/2026
    Completion :
    09/30/2027
    ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (NCT03093116)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/07/2017
    Primary completion :
    02/29/2028
    Completion :
    02/29/2028
    ALK • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    ROS1 fusion
    |
    Augtyro (repotrectinib) • midazolam hydrochloride
    A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer (NCT03215511)
    Phase 1
    Bayer
    Completed
    Last update posted :
    10/30/2024
    Initiation :
    07/03/2017
    Primary completion :
    04/11/2022
    Completion :
    01/30/2023
    NTRK3 • ETV6 • NTRK
    |
    NTRK fusion
    |
    selitrectinib (BAY 2731954)
    A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors (NCT05828303)
    Phase 1
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    06/28/2024
    Primary completion :
    07/31/2025
    Completion :
    11/30/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
    |
    Augtyro (repotrectinib) • metformin
    A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (NCT06010342)
    Phase 2
    Teligene US
    Not yet recruiting
    Last update posted :
    04/10/2024
    Initiation :
    05/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    TL118
    Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM) (NCT04772235)
    Phase 1
    Instituto Oncológico Dr Rosell
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    02/11/2022
    Primary completion :
    04/01/2026
    Completion :
    06/01/2026
    ALK • MET • ROS1 • HAVCR2 • NTRK
    |
    EGFR mutation • MET amplification • EGFR T790M
    |
    Tagrisso (osimertinib) • Augtyro (repotrectinib)
    REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE) (NCT06315010)
    Phase 2
    MedSIR
    Not yet recruiting
    Last update posted :
    03/18/2024
    Initiation :
    08/01/2024
    Primary completion :
    03/01/2027
    Completion :
    04/01/2028
    ROS1
    |
    Augtyro (repotrectinib)
    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer (NCT05004116)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    08/09/2021
    Primary completion :
    08/01/2028
    Completion :
    08/01/2028
    ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
    |
    temozolomide • irinotecan • Augtyro (repotrectinib)
    A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients (NCT05828277)
    Phase 1
    Turning Point Therapeutics, Inc.
    Withdrawn
    Last update posted :
    09/26/2023
    Initiation :
    07/28/2022
    Primary completion :
    08/31/2025
    Completion :
    12/31/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK
    |
    NTRK1 fusion • NTRK2 fusion • ROS1 fusion
    |
    Augtyro (repotrectinib)
    A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations (NCT05769075)
    Phase 1
    TYK Medicines, Inc
    Recruiting
    Last update posted :
    04/24/2023
    Initiation :
    04/20/2023
    Primary completion :
    01/01/2025
    Completion :
    10/01/2025
    ALK • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion
    |
    TY-2136b
    The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors (NCT04614740)
    Phase 2
    Jiangsu vcare pharmaceutical technology co., LTD
    Recruiting
    Last update posted :
    12/13/2022
    Initiation :
    11/20/2020
    Primary completion :
    01/31/2024
    Completion :
    06/30/2024
    NTRK
    |
    NTRK positive • NTRK fusion
    |
    VC004
    A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors (NCT04996121)
    Phase 1/2
    Xuanzhu Biopharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    08/30/2022
    Initiation :
    12/06/2021
    Primary completion :
    09/01/2025
    Completion :
    06/01/2027
    ROS1 • NTRK
    |
    ROS1 fusion • ROS1 positive • NTRK fusion
    |
    XZP-5955
    Study of FCN-098 in Patients With Advanced Solid Tumor (NCT05212987)
    Phase 1
    Fochon Pharmaceuticals, Ltd.
    Recruiting
    Last update posted :
    01/28/2022
    Initiation :
    12/31/2021
    Primary completion :
    05/08/2024
    Completion :
    10/12/2024
    NTRK
    |
    NTRK positive • NTRK fusion
    |
    FCN-098
    Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion (NCT03206931)
    Phase N/A
    Bayer
    No Longer Available
    Last update posted :
    09/16/2021
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    selitrectinib (BAY 2731954)
    A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas (NCT02048488)
    Phase 1/2
    Tesaro, Inc.
    Completed
    Last update posted :
    03/26/2019
    Initiation :
    10/01/2012
    Primary completion :
    09/01/2016
    Completion :
    06/01/2018
    ALK
    |
    ALK positive
    |
    belizatinib (TSR-011)